QRC-PVD Clinical Trial - Fenofibrate in the Management of Abdominal Aortic Aneurysm Study 2 (FAME2)
This study aimed to test the effectiveness of a 24-week course of a pharmaceutical, Fenofibrate, before surgery to repair Abdominal Aortic Aneurysms (AAA).
Aneurysms slowly expand overtime at a rate of 2-4mm per year. The only treatment available is surgical intervention. No medications have been effective in slowing the growth rate of AAA. Previous studies found possible protective results in cholesterol lowering medication like Fenofibrate.
Consenting participants (140) attended our study centres a minimum of two times over 24 weeks as part of this study, which took place over four years.
The data collected from this study has been analysed and from the results, we did not see any significant change between the control and active groups.
The full publication can be accessed here: Pinchbeck, J.L., et al. (2018). Randomized Placebo-Controlled Trial Assessing the Effect of 24-Week Fenofibrate Therapy on Circulating Markers of Abdominal Aortic Aneurysm: Outcomes From the FAME-2 Trial. Journal of the American Heart Association, 20018;7:e009866 [doi: 10.1161/JAHA. 118.009866.)
See also: Rowbotham, S.E., et al. (2016) Fenofibrate in the management of AbdoMinal aortic anEurysm (FAME)-2: the study protocol for a multi-centre, randomised, placebo-controlled trial. International Journal of Clinical Trials, 3(4): 217-224 [doi:10.18203/2349-3259.ijct20163960]